Product Center
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-03-20
- Views:
(Summary description)On March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field.
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global
(Summary description)On March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-03-20 09:16
- Views:
On March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field.
According to the agreement, the core product of this overseas shipment is the influenza virus subunit vaccine (HRK-X® 3) independently developed by Ab&B Bio. This product was approved for market in January 2026 and is the first and only trivalent influenza virus subunit vaccine suitable for the entire population aged 6 months and above in China. Both parties will carry out in-depth cooperation in the registration, sales, and commercialization of products in overseas markets.
In the wave of global influenza vaccine technology iteration, "HRK-X® 3" stands out with its third-generation influenza vaccine technology, which only extracts the surface core antigen (HA/NA) of the virus, removes the internal impurities of the virus, has higher purity, lower adverse reactions, better safety, and better immune effect. Phase III clinical data shows that local adverse reactions are lower in the split vaccine group compared to the control group. Full dose vaccination can provide stronger immune protection for infants and young children, and has good safety.
HRK-X® 3 has achieved a breakthrough in achieving unified vaccination of 0.5ml dosage form for the entire population aged 6 months and above, with infants and adults receiving the same dose of protection, greatly simplifying the vaccination process and bringing more convenient and efficient operating experience to medical staff. In addition, the HRK-X® 3 thoughtfully uses VVM tags (vaccine hot tags), allowing medical staff and vaccine recipients to visually judge the effectiveness of the vaccine with the naked eye, building the last visual line of defense for vaccine safety and making every vaccination more reassuring and worry free.
In this cooperation, Ab&B Bio will leverage the overseas market resources and mature channel network deeply cultivated by Watson Hong Kong for many years to accelerate the product's entry into Southeast Asia, Latin America, the Middle East, and the southern hemisphere. As a pioneer in the strong growth of overseas business in recent years, Walvax's rich experience in international operations will equip Ab&B Bio with the "sail to the sea" for innovative technology and product advantages, helping products unleash greater potential on the global stage and truly realizing the beautiful vision of providing high-quality Chinese vaccines to the world.
The strategic partnership with Walvax is a key step in the company's global layout, "said the person in charge of Ab&B Bio." We are not only exporting a product, but also the quality standards and technical confidence of Chinese vaccines. With the dual defense line of 'quadrivalent+trivalent' high-end vaccines, we have the confidence to flexibly respond to the diverse public health needs of the world and bring health protection to more families around the world
The relevant person in charge of Walvax also pointed out that "Ab&B Bio's products have significant differentiation advantages in technology route and clinical value, which is highly in line with the company's mission of 'sowing health and creating beauty'. We believe that the launch of this high-end subunit vaccine will effectively enhance the brand image of Chinese vaccines in the international market and inject strong new momentum into the performance growth of both parties
With the continuous deepening of strategic cooperation, overseas markets will gradually open up, and the product advantages of Ab&B Bio will be deeply coordinated with the channel advantages of Walvax, which is expected to inject surging momentum into the performance growth of both parties in the coming years.
However, the value of this strategic cooperation goes far beyond the commercial win-win situation. It is also a milestone, marking that Chinese vaccine companies are moving from the past of "fighting alone" to the current "ecological win-win" situation, and opening a new chapter in the coordinated development of China's vaccine industry.
Starting from this, both sides will work together to deeply cultivate and resonate on the broad stage of global public health. Let high-quality vaccines originating from China become a solid barrier to safeguard world health; Let the wisdom and responsibility of Chinese vaccine professionals inject even greater 'Chinese strength' into the construction of a human health community.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
